Hvis der diagnosticeres interstitiel lungesygdom, skal behandlingen med cetuximab seponeres, og patienten skal modtage adækvat behandling.
If interstitial lung disease is diagnosed, cetuximab must be discontinued and the patient be treated appropriately.